ANTI-CANCER DRUGS
ISSN:0959-4973

ANTI-CANCER DRUGS

ANTI-CANCER DRUG
学科领域:医学
是否预警:不在预警名单内
是否OA:
录用周期:偏慢,4-8周
新锐分区:医学4区
年发文量:121
影响因子:2.2
JCR分区:Q3

基本信息

《抗癌药物》报告了与抗癌药物相关的临床和实验结果,并欢迎在抗癌药物设计、药物递送、药理学、激素和生物学模式以及化疗评估方面做出贡献。《抗癌药物》是一本国际性的杂志,致力于快速发表抗癌治疗药物的创新研究,旨在刺激和报告有毒和无毒抗癌药物的研究。因此,该杂志的范围将涵盖传统的细胞毒性化疗和激素或生物反应模式,如白细胞介素和免疫疗法。提交的文章要经过编辑的初步审查。有些文章可能会被退回给作者而不作进一步考虑。那些被考虑出版的出版物将接受编辑和来自审稿人库的被邀请者的进一步评估和同行评审。
0959-4973SCIE/Scopus收录
2.2
1.9
2026年3月发布
点击查看历史分区趋势    >
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
PHARMACOLOGY & PHARMACY 药学
4区
N/A
WOS期刊SCI分区  2024-2025最新升级版
按JIF指标学科分区收集子录JIF分区JIF排名百分位
学科:ONCOLOGY
SCIE
Q3
217/328
学科:PHARMACOLOGY & PHARMACY
SCIE
Q3
209/352
按JCR指标学科分区收集子录JCR分区JCR排名百分位
学科:ONCOLOGY
SCIE
Q3
184/328
学科:PHARMACOLOGY & PHARMACY
SCIE
Q3
202/353
88
121
44%容易偏慢,4-8周-医学-药学
4.5%
时间预警情况
2026年03月发布的新锐学术版不在预警名单中
2025年03月发布的2025版不在预警名单中
2024年02月发布的2024版不在预警名单中
2023年01月发布的2023版不在预警名单中
2021年12月发布的2021版不在预警名单中
2020年12月发布的2020版不在预警名单中
96.69%21.63%0.69%
CiteScore:4.10
SJR:0.532
SNIP:0.421
学科类别分区排名百分位
大类:Medicine
小类:Pharmacology (medical)
Q2
127 / 275
大类:Medicine
小类:Oncology
Q2
199 / 415
大类:Medicine
小类:Pharmacology
Q3
177 / 321
大类:Medicine
小类:Cancer Research
Q3
148 / 233

期刊高被引文献

Downregulation of miR-205 contributes to epithelial–mesenchymal transition and invasion in triple-negative breast cancer by targeting HMGB1–RAGE signaling pathway
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000705
Identification of oncogenic long noncoding RNAs CASC9 and LINC00152 in oral carcinoma through genome-wide comprehensive analysis
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000725
Sinensetin induces apoptosis and autophagy in the treatment of human T-cell lymphoma
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000756
Methylxanthine derivatives promote autophagy in gastric cancer cells targeting PTEN
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000724
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumors
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000772
5-Fluorouracil rechallenge after 5-fluorouracil-induced hyperammonemic encephalopathy
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000730
Oleanolic acid inhibits cell proliferation migration and invasion and induces SW579 thyroid cancer cell line apoptosis by targeting forkhead transcription factor A.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000777
Proapoptotic effects of novel thiazole derivative on human glioma cells
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000686
An autophagy-dependent cell death of MDA-MB-231 cells triggered by a novel Rhein derivative 4F.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000820
Ras inhibition by zoledronic acid effectively sensitizes cervical cancer to chemotherapy.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000779
Cytotoxicity and molecular activity of fenretinide and metabolites in T-cell lymphoid malignancy, neuroblastoma, and ovarian cancer cell lines in physiological hypoxia
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000696
Bacillomycin D-C16 triggers apoptosis of gastric cancer cells through the PI3K/Akt and FoxO3a signaling pathways
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000688
Liver X receptor agonist T0901317 inhibits the migration and invasion of non-small-cell lung cancer cells in vivo and in vitro
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000758
Ginsenoside Rd reverses cisplatin resistance in non-small-cell lung cancer A549 cells by downregulating the nuclear factor erythroid 2-related factor 2 pathway.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000781
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000808
Heterocyclic organobismuth(III) compound induces nonapoptotic cell death via lipid peroxidation.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000841
Pyrimethamine exerts significant antitumor effects on human ovarian cancer cells both in vitro and in vivo
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000740
Palbociclib safety and efficacy beyond Ribociclib-induced liver toxicity in metastatic hormone-receptors positive breast cancer patient.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000845
Tumor lysis syndrome associated with bortezomib: A post-hoc analysis after signal detection using the US Food and Drug Administration Adverse Event Reporting System
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000862
Tumour flare reaction in cancer treatments: a comprehensive literature review
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000814
Multicenter retrospective study to evaluate the impact of trabectedin plus pegylated liposomal doxorubicin on the subsequent treatment in women with recurrent, platinum-sensitive ovarian cancer
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000794
C188-9, a small-molecule STAT3 inhibitor, exerts an antitumor effect on head and neck squamous cell carcinoma.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000783
Evaluation of the antileukemic effects of neurokinin-1 receptor antagonists, aprepitant, and L-733,060, in chronic and acute myeloid leukemic cells.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000769
Antitumor and immunomodulatory effects of a novel multitarget inhibitor, CS2164, in mouse hepatocellular carcinoma models
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000791
Oral metronomic cyclophosphamide in advanced ovarian cancer: long-lasting clinical response in an elderly frailty patient.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000815
Myeloablative chemotherapy and autologous stem cell transplantation can lead to successful postengraftment mobilization of hematopoietic progenitors to support planned subsequent cycle(s) of high-dose chemotherapy and autografting in a patient with relapsed germ-cell tumor
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000714
Monoclonal antibody utilization characteristics in patients with multiple myeloma.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000810
Poor expression of long-chain noncoding RNA GAPLINC inhibits epithelial-mesenchymal transition, and invasion and migration of hepatocellular carcinoma cells.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000752
Paclitaxel, 5-fluorouracil, and leucovorin combination chemotherapy as first-line treatment in patients with advanced gastric cancer
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000735
Effects of 9-cis-retinoic acid on the proliferation and apoptosis of cutaneous T-cell lymphoma cells
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000692
Baicalin induces apoptosis in SW480 cells through downregulation of the SP1 transcription factor
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000708
The signaling axis of Rac1-TFEB regulates autophagy and tumorigenesis.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000816
MDR1 gene polymorphism correlated with pathological characteristics and prognosis in patients with primary hepatocellular carcinoma receiving interventional therapy
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000680
A novel small-molecule PI3K/Akt signaling inhibitor, W934, exhibits potent antitumor efficacy in A549 non-small-cell lung cancer.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000788
Methotrexate-induced senescence of human colon cancer cells depends on p53 acetylation, but not genomic aberrations
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000731
Propranolol suppresses infantile hemangioma cell proliferation and promotes apoptosis by upregulating miR-125b expression
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000762
Partial response in hairy cell leukemia with vemurafenib despite early discontinuation due to agranulocytosis.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000821
Poly (ADP-ribose) polymerase inhibitors combined with other small-molecular compounds for the treatment of ovarian cancer.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000793
Appearance of cutaneous melanoma and subcutaneous metastases in metastatic gastric carcinoma undergoing chemotherapy with oral 5-fluorouracil prodrug.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000828
Synergistic anti-tumour effects of Clostridium butyricum in combination with apatinib in CT26 colorectal tumour-bearing mice.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000817
Effect of miR-196a inhibition on esophageal cancer growth in vitro
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000823
MiR-361-5p exerts tumor-suppressing functions in gastric carcinoma by targeting syndecan-binding protein
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000846
The let-7c/HoxB7 axis regulates the cell proliferation, migration and apoptosis in hepatocellular carcinoma.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000843
Beclin1 affected by DN604 upregulates chemo-sensitivity of cervix SiHa cancer cells via inhibiting CK2-MRN-DSBs repair.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000804
A systematic review of preventive and therapeutic options for symptoms of cystitis in patients with bladder cancer receiving intravesical bacillus Calmette–Guérin immunotherapy
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000775
The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy
来源期刊:Anti-Cancer DrugsDOI:10.1097/CAD.0000000000000728
Hyperprogression after first dose of immunotherapy in a patient with radioresistant metastasis from nonsmall cell lung cancer.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000837
An astonishing case of liver-only metastatic colorectal cancer cured by FOLFOXIRI alone.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000761
Leukocytoclastic vasculitis associated with sorafenib treatment for hepatocellular carcinoma.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000840
Proanthocyanidins attenuate breast cancer-induced bone metastasis by inhibiting Irf-3/c-jun activation.
来源期刊:Anti-cancer drugsDOI:10.1097/CAD.0000000000000852

相关文章

2026年3月发布(新锐分区)
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
PHARMACOLOGY & PHARMACY 药学
4区
N/A
2025年3月升级版
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
PHARMACOLOGY & PHARMACY 药学
4区
2023年12月旧的升级版
大类学科小类学科Top期刊综述期刊
医学4区
ONCOLOGY 肿瘤学
4区
PHARMACOLOGY & PHARMACY 药学
4区